Vida Ventures

Vida Ventures’ mission is to bring science to life by advancing transformative biomedical innovations that have the potential to make a meaningful impact on the lives of patients. They want to do well by doing good for others. Vida Ventures is a bicoastal life sciences company building and investment firm, founded in 2017 by a group of scientists, physicians, entrepreneurs, and investors who are passionate about building and funding breakthroughs in biomedicine .
JG

Jill Goldstein

Associate

Arjun Goyal

Co-Founder and MD

RJ

Rajul Jain

MD

AK

Andy Kadlec

Senior Associate

Helen S. Kim

Senior MD

Mark Springel

Associate

Stefan Vitorovic

Co-Founder and MD

41 past transactions

Vigil Neuroscience

Series B in 2021
Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.

Kadiant Inc.

Seed Round in 2019
Kadiant providing high-quality applied behavior analysis therapy and services to individuals diagnosed with autism spectrum disorder.

Aktis Oncology

Series A in 2021
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes.

ReCode Therapeutics

Series A in 2020
Recode Therapeutics, Inc., a biopharmaceutical company, develops precision medicines for pulmonary diseases. Its pipeline includes programs for primary ciliary dyskinesia and nonsense mutations in cystic fibrosis. The company’s non-viral lipid nanoparticle platform enables the delivery of various payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. Recode Therapeutics, Inc. was founded in 2015 and is based in Menlo Park, California.

Kyverna Therapeutics

Series B in 2022
Kyverna Therapeutics, Inc., a cell therapy company, develops treatments and cures for serious autoimmune diseases. The company uses advanced T cell engineering and synthetic biology technologies to suppress and eliminate autoreactive immune cells at the cause of inflammatory disease. Kyverna Therapeutics, Inc. was founded in 2018 and is based in Berkeley, California.

Protego Biopharma

Venture Round in 2021
Protego Biopharma, Inc. engages in the research and development of therapeutics and diagnostics using human genetic links. It offers products in the areas of rare diseases associated with amyloidosis; early diagnosis for amyloidosis; and novel platform enabling compound screening. Protego Biopharma, Inc. was formerly known as MisfoldingDiagnostics. The company was incorporated in 2011 and is based in San Diego, California.

Allogene Therapeutics Inc

Series A in 2018
Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Allogeneic CAR T therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. This approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for CAR T treatment.

Protego Biopharma

Series A in 2021
Protego Biopharma, Inc. engages in the research and development of therapeutics and diagnostics using human genetic links. It offers products in the areas of rare diseases associated with amyloidosis; early diagnosis for amyloidosis; and novel platform enabling compound screening. Protego Biopharma, Inc. was formerly known as MisfoldingDiagnostics. The company was incorporated in 2011 and is based in San Diego, California.

Quanta Therapeutics

Series C in 2021
Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.

Remedico

Seed Round in 2019
Remedico is India's online dermatology service. The fastest and easiest way to get healthy skin and hair.

ReCode Therapeutics

Series B in 2021
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations. ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. The company was founded in 2015 and is based in Dallas, Texas.

Tectonic Therapeutic

Series A in 2021
Tectonic is a privately held biotechnology company that aims to transform the discovery of novel GPCR-targeted drugs and unlock the therapeutic utility the most challenging receptors in the class. Tectonic’s founders are at the forefront of scientific research in biochemistry and molecular pharmacology with an extensive track record of entrepreneurial achievement.

Locana

Series B in 2020
Locanabio, Inc., is an RNA-targeting gene therapy company focused on developing therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.

A2 Biotherapeutics

Series B in 2020
A2 Biotherapeutics is an early-stage biotechnology company located in Southern California that develops novel medicines for serious illnesses. We utilize an advanced targeting technology platform to increase the effectiveness of the body’s natural immune defenses.

Volastra Therapeutics, Inc.

Seed Round in 2021
Volastra Therapeutics, Inc., a biotechnology company, develops therapies for the treatment of metastatic cancers. The company offers a library of organoids derived from metastatic cancer samples to elucidate how tumors spread and devise therapeutic strategies that target chromosomal instability during the process of cancer metastasis. Volastra Therapeutics, Inc. was incorporated in 2019 and is based in New York, New York.

Homology Medicines, Inc.

Series B in 2017
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company’s various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.

Innoskel

Series A in 2020
InnoSkel operates as a biotechnology company that develops therapies for rare skeletal diseases. The company develops treatment options for a group of rare skeletal disorders known as type 2 collagenopathies which is known as Spondyloepiphyseal Dysplasia congenital. The company was incorporated in 2020 and is based in Valbonne, France.
Scorpion Therapeutics, Inc., a biotechnology company, develops next-generation precision oncology technologies for the treatment of cancer. The company develops precision oncology drugs in three areas, including therapies against known oncogenes; agents for known but currently undruggable cancer targets; and drugs for new targets. Scorpion Therapeutics, Inc. was founded in 2020 and is based in Boston, Massachusetts.

Kinnate Biopharma

Series C in 2020
Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations. The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes.

Asklepios BioPharmaceutical

Private Equity Round in 2019
Asklepios BioPharmaceutical, Inc. (AskBio) is a privately held AAV gene therapy based company founded in 2001 to advance the work of Dr. Richard Jude Samulski, former Director of the Gene Therapy Center at the University of North Carolina (UNC) from the lab into the clinic. Dr. Samulski was the first to clone AAV for therapeutic purposes. Since AskBio’s inception almost two decades ago, Dr. Samulski’s efforts have joined those of a group of widely acclaimed researchers and clinicians.
A peloton is a team of bicyclists who achieve great efficiency of motion through cooperative action. It is also the root of platoon, a nimble military unit with capabilities that exceed the sum of its component parts. Founded by Chairman of Biochemistry Steven L. McKnight of UT Southwestern Medical Center, Peloton Therapeutics represents a unique combination of innovative science, strong financial support from the Cancer Prevention Research Institute of Texas (CPRIT), and seasoned investors and management. Working in close collaboration with scientists at UT Southwestern, Peloton is advancing a promising discovery and development pipeline, comprised of several small molecule-based programs, each with a distinct target and mechanism of action. Peloton's vision is to become a major biotech company in Dallas with a passion for discovering and developing novel cancer drugs.

Kronos Bio, Inc.

Series A in 2019
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.

ReCode Therapeutics

Series A in 2020
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations. ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. The company was founded in 2015 and is based in Dallas, Texas.

Kyverna Therapeutics

Series A in 2020
Kyverna Therapeutics, Inc., a cell therapy company, develops treatments and cures for serious autoimmune diseases. The company uses advanced T cell engineering and synthetic biology technologies to suppress and eliminate autoreactive immune cells at the cause of inflammatory disease. Kyverna Therapeutics, Inc. was founded in 2018 and is based in Berkeley, California.

Centessa Pharmaceuticals

Series A in 2021
Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. The company applies an asset-centric R&D model at scale to advance a portfolio of highly validated programs led by industry-leading teams. Each program is developed by a Centessa Subsidiary and supported by a centralized infrastructure and the Centessa management team.

Kinnate Biopharma

Series B in 2019
Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations. The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes.

PACT Pharma, Inc.

Series C in 2020
Pact Pharma is a developer of personalized adoptive T cell therapies designed for the eradication of solid tumors.The company's therapies help in the identification of neo-epitopes that serve as private mutations for each patient's cancer as well as creates an opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens, enabling physicians to recognize and remove each patient's cancer cells.

Sutro Biopharma, Inc.

Series E in 2018
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

LianBio

Venture Round in 2020
LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. LianBio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics.
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company’s lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that is in Phase III clinical trials for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratitis. Oyster Point Pharma, Inc. was founded in 2015 and is headquartered in Princeton, New Jersey.

Dyne Therapeutics

Series B in 2020
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.

IconOVir Bio

Series A in 2021
IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer.
Neogene Therapeutics, Inc. develops T cell therapies to treat cancer. The company was incorporated in 2018 and is headquartered in New York, New York.

Kronos Bio, Inc.

Private Equity Round in 2020
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.
Scorpion Therapeutics, Inc., a biotechnology company, develops next-generation precision oncology technologies for the treatment of cancer. The company develops precision oncology drugs in three areas, including therapies against known oncogenes; agents for known but currently undruggable cancer targets; and drugs for new targets. Scorpion Therapeutics, Inc. was founded in 2020 and is based in Boston, Massachusetts.

A2 Biotherapeutics

Series A in 2019
A2 Biotherapeutics is an early-stage biotechnology company located in Southern California that develops novel medicines for serious illnesses. We utilize an advanced targeting technology platform to increase the effectiveness of the body’s natural immune defenses.

Kronos Bio, Inc.

Seed Round in 2018
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.

A2 Biotherapeutics

Seed Round in 2019
A2 Biotherapeutics is an early-stage biotechnology company located in Southern California that develops novel medicines for serious illnesses. We utilize an advanced targeting technology platform to increase the effectiveness of the body’s natural immune defenses.
Praxis Precision Medicines offers drug development services. The company was formerly known as EpiPM Therapeutics. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.
Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.